More Information Product Details Synonyms Product Type Properties Source/Host Sequence Crossreactivity Formulation Other Product Data Declaration Shipping and Handling Shipping Short Term Storage Long Term Storage Handling Advice Use/Stability Documents MSDS Product Specification Sheet Datasheet

Small Ubiquitin-related Modifier 3; HSMT3; SMT3 Homolog 1; Ubiquitin-like Protein SMT3B

Protein

E. coli

Human Pro-SUMO3 (Accession Nr. P55854) fused to a N-terminal His-tag.

Human

Liquid. In 50mM HEPES pH 8.0, 150mM NaCl, 1mM DTT.

Use: Can be used as a negative control in sumolyation reactions or as a substrate for SENPs. Typical in vitro concentrations are 10-50μM depending on conditions.

Manufactured by Boston Biochem

DRY ICE

-20°C

-80°C

Aliquot to avoid freeze/thaw cycles.

Stable for at least 1 year after receipt when stored at -80°C.

No

Download PDF

Small Ubiquitin-like Modifier 3 (SUMO3), also known as SMT3A, is synthesized as a 103 amino acid (aa), propeptide with a predicted 11.5 kDa. SUMO3 contains a two aa C-terminal prosegment. Human SUMO3 shares 83% sequence identity with mouse SUMO3. SUMO3 also has high aa sequence homology to SUMO2 and SUMO4, 87% and 75%, respectively. SUMO3 shares only 47% sequence identity with SUMO1. SUMOs are a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed SUMOylation. All SUMO proteins share a conserved ubiquitin domain and a C-terminal diglycine cleavage/attachment site. Following prosegment cleavage, the C-terminal glycine residue of SUMO3 is enzymatically attached to a lysine residue on a target protein. In humans, SUMO3 is conjugated to a variety of molecules in the presence of the SAE1/UBA2 SUMO-activating (E1) enzyme and the UBE2I/Ubc9 SUMO-conjugating (E2) enzyme. In yeast, the SUMO-activating (E1) enzyme is Aos1/Uba2p. Because of the high level of sequence homology most studies report effects of SUMO2/3. For example, addition of SUMO2/3 was shown to modulate the function of ARHGAP21, a RhoGAP protein known to be involved in cell migration. Other reports indicate that the conjugation by SUMO2/3, but not SUMO1, may represent an important mechanism to protect neurons during episodes of cerebral ischemia. However, studies suggest that SUMO2/3 expression is regulated in an isoform-specific manner since oxidative stress downregulated the transcription of SUMO3, but not SUMO2. All SUMO isoforms are translated with additional C-terminal residues that have to be removed to generate the active protein. Pro-SUMO-3 (103 aa) is the inactive precursor of SUMO-3 (92 aa) and is processed at the C-terminus by SUMO-3 specific proteases (SENPs).The resulting SUMO-3 protein has the conserved C-terminal Gly-Gly residues that function in activation and conjugation reactions.